R. Smith

UGT2B17 Genetic Polymorphisms Dramatically Affect the Pharmacokinetics of MK-7246 in Healthy Subjects in a First-in-Human Study

J. McElwee, G. Opiteck, J. Klappenbach, 2012, Clinical pharmacology and therapeutics.

DNA-methylation gene network dysregulation in peripheral blood lymphocytes of schizophrenia patients

A. Lajtha, A. Guidotti, E. Dong, 2013, Schizophrenia Research.

An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes

A. Lajtha, A. Guidotti, E. Costa, 2009, Schizophrenia Research.

Toward the Identification of Peripheral Epigenetic Biomarkers of Schizophrenia

A. Guidotti, E. Dong, D. Grayson, 2014, Journal of neurogenetics.

Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project

M. Rietschel, I. Craig, A. Farmer, 2011, The Pharmacogenomics Journal.

Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3′-untranslated region

D. Lancet, K. Kanyas, B. Lerer, 2009, The Pharmacogenomics Journal.

Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia

B. Lerer, R. Segman, V. Pavlov, 2008, The Pharmacogenomics Journal.